Vaccines Xagena

Xagena Mappa
Xagena Newsletter

Safety of smallpox vaccine

Most people experience normal, usually mild reactions that include a sore arm, fever, and body aches. In recent tests, one in three people felt bad enough to miss work, school, or recreational activity or had trouble sleeping after receiving the vaccine. However, the vaccine does have some risks.
In the past, about 1,000 people for every 1 million people vaccinated for the first time experienced reactions that, while not life-threatening, were serious. These reactions include a vigorous ( toxic or allergic ) reaction at the site of the vaccination and spread of the vaccinia virus ( the live virus in the smallpox vaccine ) to other parts of the body and to other people. These reactions typically do not require medical attention. Rarely, people have had very bad reactions to the vaccine.
In the past, between 14 and 52 people per 1 million vaccinated experienced potentially life-threatening reactions, including eczema vaccinatum, progressive vaccinia ( or vaccinia necrosum ), or postvaccinal encephalitis.
Based on past experience, it is estimated that between 1 and 2 people out of every 1 million people vaccinated may die as a result of life-threatening reactions to the vaccine.

Careful screening of potential vaccine recipients is essential to ensure that those at increased risk do not receive the vaccine. People most likely to have side effects are those who have, or even once had, skin conditions ( especially eczema or atopic dermatitis ), and people with weakened immune systems, such as those who have received a transplant, are HIV positive, or are receiving treatment for cancer.
Anyone who falls within these categories, or lives with someone who falls into one of these categories, should not get the smallpox vaccine unless they are exposed to the disease.
Pregnant women should not get the vaccine because of the risk it poses to the fetus.
Women who are breastfeeding should not get the vaccine.
Children younger than 12 months of age should not get the vaccine.

Historically re-vaccinees have had less severe adverse events, but since routine vaccination was stopped globally 20 years ago, most people may be assumed to have low to no protective immunity to smallpox.
Therefore, re-vaccinees may have similar rates of reactions as first-time vaccinees.

A person did not experience an adverse reaction to the vaccine in childhood does not mean that they will not experience adverse reactions as an adult. Many of the conditions that increase the likelihood of serious adverse reactions may not have been present in childhood ( e.g. skin conditions, taking medication that suppresses the immune system ).

Myocarditis has been reported previously following smallpox vaccination in Europe, but had not been a well-accepted complication following vaccination with the US-licensed New York City Board of Health vaccine.
Coronary events, including angina or myocardial infarction, have not been previously associated with smallpox vaccine.
The current smallpox vaccination program may differ from historical experience because a greater number of older patients with underlying heart disease and cardiac risk factors such as hypertension and diabetes mellitus may be receiving vaccinations.
Moreover, because current diagnostic tests, including cardiac enzymes and echocardiography, are more sensitive for diagnosing myocardial infarction, more events may be detected than were historically observed.

Cardiac-associated death following smallpox vaccination, although extremely rare, has been reported in Europe and Australia and has been thought to be associated with myocarditis.
However, a death certificate study of vaccinia-associated deaths in the U.S. over a 20-year period did not identify any deaths associated with cardiac complications.
The US Centres for Disease Control and Prevention ( CDC ) reports that it is not clear whether the number of events that have recently occurred in the US is greater than would be expected.
A certain number of cardiac events and deaths following vaccination would be expected to occur by chance alone, given both how common cardiac problems are and the numbers of people vaccinated in the US civilian program. ( Xagena )

Source: World Health Organization ( WHO ), 2009